Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dawn C Buse

Showing results (61-70 of 230) with videos related to

Pageof 23
Sort By:
Headache|June 29, 2016
A Comparison of the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study and American Migraine Prevalence and Prevention (AMPP) Study: Demographics and Headache-Related DisabilityRichard B Lipton, Aubrey Manack Adams, Dawn C Buse, et al.
Headache|September 8, 2017
Faster Improvement in Migraine Pain Intensity and Migraine-Related Disability at Early Time Points with AVP-825 (Sumatriptan Nasal Powder Delivery System) versus Oral Sumatriptan: A Comparative Randomized Clinical Trial Across Multiple Attacks from the COMPASS StudyRichard B Lipton, James S McGinley, Kenneth J Shulman, et al.
Headache|June 21, 2018
Acceptance, Psychiatric Symptoms, and Migraine Disability: An Observational Study in a Headache CenterElizabeth K Seng, Alexander J Kuka, Sarah Jo Mayson, et al.
International Journal of General Medicine|March 4, 2015
Prophylactic onabotulinumtoxinA in patients with chronic migraine and comorbid depression: An open-label, multicenter, pilot study of efficacy, safety and effect on headache-related disability, depression, and anxietyGuy P Boudreau, Brian M Grosberg, Peter J McAllister, et al.
Headache|October 13, 2016
Predicting Inadequate Response to Acute Migraine Medication: Results From the American Migraine Prevalence and Prevention (AMPP) StudyRichard B Lipton, Sagar Munjal, Dawn C Buse, et al.
Psychiatric Services (Washington, D.C.)|May 30, 2003
A comparison of gynecological variables and service use among older women with and without schizophreniaLaurie A Lindamer, Dawn C Buse, Lisa Auslander, et al.
Journal of Occupational and Environmental Medicine|September 14, 2011
A case study for calculating employer costs for lost productive time in episodic migraine and chronic migraine: results of the American Migraine Prevalence and Prevention StudyWalter F Stewart, Christa Bruce, Aubrey Manack, et al.
Neurology|January 23, 2015
Ineffective acute treatment of episodic migraine is associated with new-onset chronic migraineRichard B Lipton, Kristina M Fanning, Daniel Serrano, et al.
Headache|October 20, 2012
Barriers to the diagnosis and treatment of migraine: effects of sex, income, and headache featuresRichard B Lipton, Daniel Serrano, Starr Holland, et al.
Journal of the Neurological Sciences|February 12, 2013
Rates and reasons for discontinuation of triptans and opioids in episodic migraine: results from the American Migraine Prevalence and Prevention (AMPP) studyStarr Holland, Kristina M Fanning, Daniel Serrano, et al.
Pageof 23

Showing results (61-70 of 230) with videos related to

Sort By:
Pageof 23
Headache|June 29, 2016
A Comparison of the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study and American Migraine Prevalence and Prevention (AMPP) Study: Demographics and Headache-Related DisabilityRichard B Lipton, Aubrey Manack Adams, Dawn C Buse, et al.
Headache|September 8, 2017
Faster Improvement in Migraine Pain Intensity and Migraine-Related Disability at Early Time Points with AVP-825 (Sumatriptan Nasal Powder Delivery System) versus Oral Sumatriptan: A Comparative Randomized Clinical Trial Across Multiple Attacks from the COMPASS StudyRichard B Lipton, James S McGinley, Kenneth J Shulman, et al.
Headache|June 21, 2018
Acceptance, Psychiatric Symptoms, and Migraine Disability: An Observational Study in a Headache CenterElizabeth K Seng, Alexander J Kuka, Sarah Jo Mayson, et al.
International Journal of General Medicine|March 4, 2015
Prophylactic onabotulinumtoxinA in patients with chronic migraine and comorbid depression: An open-label, multicenter, pilot study of efficacy, safety and effect on headache-related disability, depression, and anxietyGuy P Boudreau, Brian M Grosberg, Peter J McAllister, et al.
Headache|October 13, 2016
Predicting Inadequate Response to Acute Migraine Medication: Results From the American Migraine Prevalence and Prevention (AMPP) StudyRichard B Lipton, Sagar Munjal, Dawn C Buse, et al.
Psychiatric Services (Washington, D.C.)|May 30, 2003
A comparison of gynecological variables and service use among older women with and without schizophreniaLaurie A Lindamer, Dawn C Buse, Lisa Auslander, et al.
Journal of Occupational and Environmental Medicine|September 14, 2011
A case study for calculating employer costs for lost productive time in episodic migraine and chronic migraine: results of the American Migraine Prevalence and Prevention StudyWalter F Stewart, Christa Bruce, Aubrey Manack, et al.
Neurology|January 23, 2015
Ineffective acute treatment of episodic migraine is associated with new-onset chronic migraineRichard B Lipton, Kristina M Fanning, Daniel Serrano, et al.
Headache|October 20, 2012
Barriers to the diagnosis and treatment of migraine: effects of sex, income, and headache featuresRichard B Lipton, Daniel Serrano, Starr Holland, et al.
Journal of the Neurological Sciences|February 12, 2013
Rates and reasons for discontinuation of triptans and opioids in episodic migraine: results from the American Migraine Prevalence and Prevention (AMPP) studyStarr Holland, Kristina M Fanning, Daniel Serrano, et al.
Pageof 23